Management of hyperglycemia in type 2 diabetes: a patient-centere

Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes

Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364–79. doi:10.​2337/​dc12-0413dc12-0413.PubMedCentralPubMedCrossRef 20. Malerczyk V, Badian M, Korn A, Lehr KH, Waldhausl W. Dose linearity assessment of glimepiride (Amaryl) tablets in healthy volunteers. Drug Metabol Drug Interact. 1994;11:341–57.PubMedCrossRef 21. Rosenkranz B. Pharmacokinetic BYL719 clinical trial basis for the safety of glimepiride in risk groups of NIDDM patients. Horm Metab Res. 1996;28:434–9. doi:10.​1055/​s-2007-979833.PubMedCrossRef 22. Sanofi-aventis (2013). AMARYL (glimepiride) tablets. FDA. http://​www.​accessdata.​fda.​gov/​drugsatfda_​docs/​label/​2013/​020496s027lbl.​pdf. Accessed 3 Dec 2013. 23. Declaration of Helsinki. Ethical principles for medical research involving human subjects. World Medical Association; 2008. http://​www.​wma.​net/​en/​30publications/​10policies/​b3/​17c.​pdf.

MM-102 in vivo Accessed 3 Dec 2013. 24. ICH. Guideline for Good Clinical find more Practice E6 (R1). ICH Harmonised Tripartite Guideline; 1996. http://​www.​ich.​org/​fileadmin/​Public_​Web_​Site/​ICH_​Products/​Guidelines/​Efficacy/​E6_​R1/​Step4/​E6_​R1_​_​Guideline.​pdf. Accessed 2 Dec 2013. 25. Rowland M, Tozer T. Clinical pharmacokinetics and pharmacodynamics: concepts and applications. Philadelphia: Lippincott Williams & Wilkins; 2011. 26. FDA. Guidance for Industry. Drug interaction studies: study design, data analysis, implications for dosing, and labeling recommendations. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER); 2012. http://​www.​fda.​gov/​downloads/​Drugs/​GuidanceComplian​ceRegulatoryInfo​rmation/​Guidances/​UCM292362.​pdf. Accessed 3 Dec 2013. 27. Chen

L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus–present and future perspectives. Nat Rev Endocrinol. selleck chemicals 2012;8:228–36. doi:10.​1038/​nrendo.​2011.​183nrendo.​2011.​183.CrossRef 28. CDC. National diabetes fact sheet. US Department of Health and Human Services; 2011. http://​www.​cdc.​gov/​diabetes/​pubs/​pdf/​ndfs_​2011.​pdf. 29. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–12.PubMedCentralPubMedCrossRef 30. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193–203. doi:10.​2337/​dc08-9025.

Comments are closed.